Analysts Set Expectations for LMAT FY2024 Earnings

LeMaitre Vascular, Inc. (NASDAQ:LMAT) – Research analysts at Barrington Research lifted their FY2024 earnings estimates for shares of LeMaitre Vascular in a research report issued on Friday, November 1st. Barrington Research analyst M. Petusky now anticipates that the medical instruments supplier will earn $1.94 per share for the year, up from their previous estimate of $1.87. Barrington Research has a “Outperform” rating and a $93.00 price objective on the stock. The consensus estimate for LeMaitre Vascular’s current full-year earnings is $1.94 per share. Barrington Research also issued estimates for LeMaitre Vascular’s Q4 2024 earnings at $0.49 EPS, Q1 2025 earnings at $0.54 EPS, Q3 2025 earnings at $0.55 EPS and FY2025 earnings at $2.28 EPS.

A number of other equities analysts have also commented on LMAT. Oppenheimer reissued an “outperform” rating and set a $93.00 price target (up from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Cantor Fitzgerald assumed coverage on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price objective on the stock. Lake Street Capital began coverage on shares of LeMaitre Vascular in a research note on Friday, August 2nd. They set a “buy” rating and a $105.00 target price for the company. StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th. Finally, JMP Securities boosted their price target on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a report on Tuesday, August 20th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $94.57.

LeMaitre Vascular Stock Up 2.4 %

Shares of LeMaitre Vascular stock opened at $98.63 on Monday. The stock’s 50-day simple moving average is $89.88 and its 200-day simple moving average is $83.74. LeMaitre Vascular has a 52 week low of $47.72 and a 52 week high of $101.67. The company has a market capitalization of $2.22 billion, a price-to-earnings ratio of 53.90, a PEG ratio of 2.38 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.05. The company had revenue of $54.82 million during the quarter, compared to analyst estimates of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The firm’s quarterly revenue was up 15.6% compared to the same quarter last year. During the same period in the previous year, the business posted $0.33 earnings per share.

Hedge Funds Weigh In On LeMaitre Vascular

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in shares of LeMaitre Vascular by 2.5% in the fourth quarter. Vanguard Group Inc. now owns 1,548,870 shares of the medical instruments supplier’s stock worth $87,914,000 after buying an additional 38,303 shares in the last quarter. Norden Group LLC acquired a new position in LeMaitre Vascular during the first quarter worth $401,000. BNP Paribas Financial Markets boosted its position in shares of LeMaitre Vascular by 135.6% during the first quarter. BNP Paribas Financial Markets now owns 22,917 shares of the medical instruments supplier’s stock worth $1,521,000 after buying an additional 13,189 shares during the period. Texas Permanent School Fund Corp grew its stake in shares of LeMaitre Vascular by 1.3% in the first quarter. Texas Permanent School Fund Corp now owns 17,341 shares of the medical instruments supplier’s stock valued at $1,151,000 after buying an additional 225 shares in the last quarter. Finally, Envestnet Portfolio Solutions Inc. acquired a new position in LeMaitre Vascular during the 1st quarter worth about $206,000. Hedge funds and other institutional investors own 84.64% of the company’s stock.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, Director David B. Roberts sold 3,063 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total transaction of $251,380.41. Following the completion of the transaction, the director now directly owns 14,114 shares of the company’s stock, valued at approximately $1,158,335.98. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 10.79% of the stock is owned by insiders.

LeMaitre Vascular Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 5th. Investors of record on Thursday, November 21st will be issued a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.65%. The ex-dividend date is Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is 34.97%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.